Consistent with the knockdown data, thymidine supplementation completely rescued the viability defects in MTHFD2 inhibitor-treated HL-60 cells, a trend also observed in THP-1 AML cells and SW620 colorectal cancer cells (Fig. 4a and Extended Data Fig. 3). Here, MTHFD2 is linked to colorectal cancer.